WSH
Bluelighter
- Joined
- Nov 30, 2012
- Messages
- 360
Thank you for your thorough reply.
It's true that I've completely forgotten to check the in vivo evidence.
That reminds me of 8-OH-DPAT. They have proven in vitro that it's a full agonist at inhibiting forskolin-stimulated cAMP production at postsynaptic 5-HT1A receptors in the hippocampus.
But then Montigny came along and proved that it's actually a rather weak partial agonist using in vivo electrophysiology.
So yeah, in vivo > in vitro.
I agree, MK-801 does NOT seem to produce its effects via D2 in vivo.
It's true that I've completely forgotten to check the in vivo evidence.
That reminds me of 8-OH-DPAT. They have proven in vitro that it's a full agonist at inhibiting forskolin-stimulated cAMP production at postsynaptic 5-HT1A receptors in the hippocampus.
But then Montigny came along and proved that it's actually a rather weak partial agonist using in vivo electrophysiology.
So yeah, in vivo > in vitro.
I agree, MK-801 does NOT seem to produce its effects via D2 in vivo.
Last edited: